U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

               [ X ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002

                                       OR

               [ ] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

           FOR THE TRANSITION PERIOD FROM ____________ TO ___________

                          Commission File No. 33351414



                           Rubicon Medical Corporation
                           ---------------------------
        (Exact name of small business issuer as specified in its charter)



Delaware                                                              87-0361403
-------------------------------                              -------------------
(State or other jurisdiction of                                    (IRS Employer
incorporation or organization)                               Identification No.)



2064 W. Alexander, Salt Lake City, Utah                                    84119
---------------------------------------                               ----------
(Address of principal executive offices)                              (Zip Code)

          Issuer's telephone number, including area code:(801) 886-9000
                                                          -------------


Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15 (d) of the  Securities  Exchange  Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),  and
(2) has been subject to such filing requirements for the past 90 days.

                              YES X             NO


The Issuer had 52,378,334 outstanding shares of common stock on August 1, 2002.

<PAGE>

                           Rubicon Medical Corporation
                           ---------------------------


                                      INDEX
                                      -----


   PART 1. FINANCIAL INFORMATION                                         Page
                                                                         ----


   Consolidated Balance Sheet - June 30, 2002 (Unaudited)                  2

   Consolidated Statement of Operations - Three-
     and Six Months Ended June 30, 2002 and 2001 (Unaudited)               3

   Consolidated Statement of Cash Flows - Six Months Ended
     June 30, 2002 and 2001 (Unaudited)                                    4

   Notes to Consolidated Financial Statements (Unaudited)                  6

   Management's Discussion and Analysis of Financial
     Condition and Results of Operations                                   9


PART II. OTHER INFORMATION                                                12


SIGNATURES                                                                13


CERTIFICATIONS                                                            14
<PAGE>



                          Part I. Financial Information

                          Item I. Financial Statements
                           Rubicon Medical Corporation
                              Financial Statements
                                   (Unaudited)

                  FORWARD LOOKING INFORMATION AND RISK FACTORS

         Rubicon Medical  Corporation (the "Company") or its representatives may
make forward looking statements,  oral or written,  including statements in this
report's Management's Discussion and Analysis of Financial Condition and Results
of  Operation,  press  release  and filings  with the  Securities  and  Exchange
Commission,  regarding  estimated future net revenues from  operations,  planned
capital  expenditures  (including the amount and nature thereof),  the Company's
projected financial position, results of operations, business strategy and other
plans and objectives for future operations. These statements are forward-looking
statements,  within the meaning of Section 27A of the Securities Act of 1993 and
Section 21E of the Securities Exchange Act, which reflect  Management's  current
views with respect to future events and financial performance.

         Although the Company believes that the expectations  reflected in these
forward looking  statements are  reasonable,  there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected effects on its
business or results of operations. Such forward-looking statements involve known
and unknown  risks,  uncertainties  and other factors which may cause the actual
results,  performance or achievements of the Company to be materially  different
from any future  results,  performance or  achievements  expressed or implied by
such forward-looking statements. Such factors include but are not limited to the
Company's   manufacturing  process,   reaching  the  milestones  of  the  Abbott
Agreement,  engineering  difficulties,   difficulties  in  connection  with  the
Company's business operations and other risks.

         These  forward-looking  statements  are  subject to  certain  risks and
uncertainties  including,  but not limited to, future financial  performance and
future events,  competitive pricing for services,  costs of obtaining capital as
well as national,  regional and local economic conditions.  Actual results could
differ materially from those addressed in the forward-looking statements. Due to
such uncertainties and risks,  readers are cautioned not to place undue reliance
on such forward-looking statements, which speak only as of the date whereof.

         All subsequent oral and written forward-looking statements attributable
to the Company or persons acting on its behalf are expressly  qualified in their
entirety by these  factors.  The Company  assumes no obligation to update any of
these statements.

<PAGE>
<TABLE>
<CAPTION>

                                                                               RUBICON MEDICAL CORPORATION

                                                                    Consolidated Balance Sheet (Unaudited)

                                                                                             June 30, 2002
----------------------------------------------------------------------------------------------------------




              Assets
              ------
<S>                                                                                       <C>
Current assets:
     Cash and cash equivalents                                                            $         58,000
     Accounts receivable, net                                                                        3,000
     Income tax receivable                                                                         134,000
     Prepaid expenses                                                                               15,000
     Net assets from discontinued operations                                                        44,000
                                                                                          ----------------

                  Current assets                                                                   254,000

Property and equipment, net                                                                        221,000
Intangible assets, net                                                                              58,000
                                                                                          ----------------

                  Total assets                                                            $        533,000
                                                                                          ----------------

----------------------------------------------------------------------------------------------------------

              Liabilities and Stockholders' Equity
              ------------------------------------

Current liabilities:
     Accounts payable                                                                     $        127,000
     Convertible note payable                                                                       50,000
     Current portion of long-term debt                                                              30,000
                                                                                          ----------------

                  Total current liabilities                                                        207,000

Long-term debt                                                                                      46,000
Related party long-term debt                                                                       155,000
                                                                                          ----------------

                  Total liabilities                                                                408,000
                                                                                          ----------------

Commitments and contingencies                                                                            -

Stockholders' equity:
     Common stock, $.001 par value, 100,000,000 shares
       authorized; 52,178,334 shares issued and outstanding                                         52,000
     Additional paid-in-capital                                                                  3,111,000
     Deferred compensation                                                                         (78,000)
     Treasury stock                                                                                (65,000)
     Accumulated deficit                                                                        (2,895,000)
                                                                                          ----------------

                  Total stockholders' equity                                                       125,000
                                                                                          ----------------

                  Total liabilities and stockholders' equity                              $        533,000
                                                                                          ----------------

----------------------------------------------------------------------------------------------------------
See notes to consolidated financial statements.
                                                                                                         2
</TABLE>
<PAGE>
<TABLE>
<CAPTION>

                                                                               RUBICON MEDICAL CORPORATION
                                                          Consolidated Statement of Operations (Unaudited)

----------------------------------------------------------------------------------------------------------




                                                  Three Months Ended              Six Months Ended
                                                       June 30,                       June 30,
                                            --------------------------------------------------------------
                                                  2002           2001           2002            2001
                                            --------------------------------------------------------------

<S>                                         <C>               <C>            <C>            <C>
Net sales                                   $        117,000  $     464,000  $     117,000  $    1,066,000
Cost of sales                                          3,000         71,000          3,000         102,000
                                            --------------------------------------------------------------

         Gross profit                                114,000        393,000        114,000         964,000
                                            --------------------------------------------------------------

Operating expenses:
   Depreciation and amortization                      44,000         22,000         88,000          67,000
   General and administrative                        242,000        150,000        566,000         335,000
   Research and development                          189,000         83,000        320,000         258,000
                                            --------------------------------------------------------------

                                                     475,000        255,000        974,000         660,000
                                            --------------------------------------------------------------

         Income (loss) from operations              (361,000)       138,000       (860,000)        304,000
                                            --------------------------------------------------------------

Other income (expense):
   Interest income                                         -         15,000          1,000          37,000
   Interest expense                                  (53,000)        (9,000)       (60,000)        (23,000)
   Other                                                   -         (8,000)             -          (8,000)
                                            --------------------------------------------------------------

         Other income (expense)                      (53,000)        (2,000)       (59,000)          6,000
                                            --------------------------------------------------------------

         Income (loss) before provision for
           income taxes                             (414,000)       136,000       (919,000)        310,000
                                            --------------------------------------------------------------

Income tax (expense) benefit:
   Current                                                 -        163,000              -         163,000
   Deferred                                                -       (179,000)             -        (275,000)
                                            --------------------------------------------------------------

                                                           -        (16,000)             -        (112,000)

         Income (loss) from discontinued
            operations                                (8,000)        28,000        (16,000)        (71,000)
                                            --------------------------------------------------------------

         Net income (loss)                  $       (422,000) $      92,000  $    (935,000) $      127,000
                                            --------------------------------------------------------------

Net loss per common share -
  basic and diluted                         $           (.01) $         .00  $        (.02) $          .00

                                            --------------------------------------------------------------

Weighted average shares - basic and diluted       51,977,000     48,508,000     51,977,000      48,508,000
                                            --------------------------------------------------------------


----------------------------------------------------------------------------------------------------------
See notes to consolidated financial statements.                                                          3
</TABLE>
<PAGE>
<TABLE>
<CAPTION>


                                                                               RUBICON MEDICAL CORPORATION
                                                          Consolidated Statement of Cash Flows (Unaudited)

----------------------------------------------------------------------------------------------------------


                                                                                  Six Months Ended
                                                                                      June 30,
                                                                           -------------------------------
                                                                                2002            2001
                                                                           -------------------------------
<S>                                                                        <C>              <C>
Cash flows from operating activities:
Net (loss) income                                                          $      (935,000) $      127,000
Loss from discontinued operations                                                   16,000          71,000
Adjustments to reconcile net (loss) income to net cash
  used in operating activities:
   Depreciation and amortization                                                    88,000          72,000
   Amortization of deferred compensation                                            42,000               -
   Common stock issued for services                                                      -         121,000
   Effective interest on beneficial conversion feature                              50,000               -
   Deferred income taxes                                                                 -         275,000
   Loss on disposal of assets                                                            -           8,000
   (Increase) decrease in:
     Accounts receivable                                                           173,000         145,000
     Prepaid expenses                                                                6,000          (1,000)
     Income tax receivable                                                          29,000        (163,000)
   Increase (decrease) in:
     Accounts payable                                                               12,000           9,000
     Accrued liabilities                                                            (3,000)         (1,000)
     Deferred revenue                                                                    -        (666,000)
     Income tax payable                                                                  -        (274,000)
                                                                           -------------------------------

         Net cash used in continuing operations                                   (522,000)       (277,000)
         Net cash used in discontinued operations                                  (54,000)       (135,000)
                                                                           -------------------------------

         Net cash used in
         operating activities                                                     (576,000)       (412,000)
                                                                           -------------------------------

Cash flows from investing activities:
   Increase in intangible assets                                                   (43,000)              -
   Purchase of property and equipment                                               (7,000)        (50,000)
                                                                           -------------------------------

         Net cash used in continuing operations                                    (50,000)        (50,000)
         Net cash (used in) discontinued operations                                      -          (3,000)
                                                                           -------------------------------

         Net cash used in investing activities                                     (50,000)        (53,000)
                                                                           -------------------------------

Cash flows from financing activities:
   Principal payments on long-term debt                                            (48,000)        (60,000)
   Proceeds from related party long-term debt                                      155,000               -
   Proceeds from convertible note payable                                           50,000               -
   Purchase of treasury stock                                                      (65,000)              -
   Proceeds from issuance of common stock                                          246,000               -
                                                                           -------------------------------

         Net cash provided by (used in) continuing operations                      338,000         (60,000)
         Net cash used in discontinued operations                                  (20,000)       (268,000)
                                                                           -------------------------------

         Net cash provided by (used in)
         financing activities                                                      318,000        (328,000)
                                                                           -------------------------------

Net decrease in cash and cash equivalents                                         (308,000)       (793,000)

Cash and cash equivalents at beginning of period                                   366,000       1,421,000
                                                                           -------------------------------

Cash and cash equivalents at end of period                                 $        58,000   $     628,000
                                                                           -------------------------------


----------------------------------------------------------------------------------------------------------
See notes to consolidated financial statements.                                                          4
</TABLE>
<PAGE>

                                                     RUBICON MEDICAL CORPORATION
                                Consolidated Statement of Cash Flows (Unaudited)
                                                                       Continued

--------------------------------------------------------------------------------


Supplemental Cash Flow Information (unaudited):

During the six months ended June 30, 2001, the Company:

     o  Issued common stock in exchange for debt of $200,000.

     o  Issued common stock in satisfaction of a liability of $280,000.



                                                     Six Months Ended
                                                          June 30,
                                             -----------------------------------
                                                   2002              2001
                                             -----------------------------------

Cash paid during the period for:
     Interest                                $          10,000  $       23,000
                                             -----------------------------------

     Income taxes                            $               -  $            -
                                             -----------------------------------




--------------------------------------------------------------------------------
See notes to consolidated financial statements.                                5
<PAGE>

                                                     RUBICON MEDICAL CORPORATION
                          Notes to Consolidated Financial Statements (Unaudited)

                                                                   June 30, 2002
--------------------------------------------------------------------------------


1.   Interim             The  consolidated  financial  statements  for  the  six
     Financial           months  ended June 30,  2002 and 2001,  are  unaudited.
     Statements          However,  the  Company,  in its  opinion,  has made all
                         adjustments   (consisting   only  of  normal  recurring
                         accruals)  necessary  to present  fairly the  financial
                         position,  results of operations and cash flows for the
                         periods   presented.    The   consolidated    financial
                         statements   and  notes  thereto   should  be  read  in
                         conjunction with the consolidated  financial statements
                         and notes for the years  ended  December  31,  2001 and
                         2000,  included  in the  Company's  Form 10KSB filed on
                         March  28,  2002  with  the   Securities  and  Exchange
                         Commission.  The results of  operations  and cash flows
                         for  the  six  months  ended  June  30,  2002,  are not
                         necessarily  indicative  of results for the year ending
                         December 31, 2002.


2.   Loss Per            Basic loss per share excludes  dilution and is computed
     Share               by dividing net losses available to common stockholders
                         by  the  weighted   average  number  of  common  shares
                         outstanding for the period.  Diluted earnings per share
                         reflect  the  potential  dilution  that could  occur if
                         options  or  warrants  to  issue   common   stock  were
                         exercised into common stock.  Common stock  equivalents
                         are  not   included  in  the  diluted  loss  per  share
                         calculation when their effect is antidilutive.


3.   Discontinued        In an effort to maximize growth and attain  high-margin
     Operations          revenues,  management has determined to focus solely on
                         the technology development segment and has discontinued
                         the contract manufacturing and equipment  manufacturing
                         segments of its operations.  The Company  recognized an
                         estimated   loss   on   disposition   of   discontinued
                         operations  of $582,000  as of the year ended  December
                         31, 2001.



--------------------------------------------------------------------------------
                                                                               6
<PAGE>

                                                     RUBICON MEDICAL CORPORATION
                          Notes to Consolidated Financial Statements (Unaudited)
                                                                       Continued

--------------------------------------------------------------------------------


3.   Discontinued        Net assets and condensed discontinued  operations as of
     Operations          June 30, 2002 are as follows:
     Continued

                 Assets:
                  Inventory                                $         11,000
                  Property and equipment                            157,000
                                                           ----------------

                                                           $        168,000
                                                           ----------------



                Liabilities:
                 Notes payable                             $       (124,000)
                                                           ----------------

                Net assets of discontinued operations      $         44,000
                                                           ----------------



                                                  Six Months Ended
                                                       June 30
                                          ---------------------------------
                                                2002             2001
                                          ---------------------------------

Revenue                                   $          76,000  $      286,000
Costs and expenses                                   92,000         393,000
                                          ---------------------------------

Net loss before income taxes                        (16,000)       (107,000)

Income taxes                                              -          36,000
                                          ---------------------------------

                                          $         (16,000) $      (71,000)
                                          ---------------------------------



4.   Related Party       At June 30,  2002,  the Company had a note payable to a
     Transaction         shareholder for $155,000.  The note has a 6.5% interest
                         rate and is due January 31, 2003. During the six months
                         ended June 30, 2002,  $117,000 of revenue was generated
                         from work done for Guardian  RJL, a company owned by an
                         officer.


--------------------------------------------------------------------------------
                                                                               7
<PAGE>

                                                     RUBICON MEDICAL CORPORATION
                          Notes to Consolidated Financial Statements (Unaudited)
                                                                       Continued

--------------------------------------------------------------------------------



5.   Subsequent          During the  quarter  ended June 30,  2002,  the Company
     Event               issued a  $50,000 convertible  debenture.  The terms of
                         the  debenture  allowed  the holder to convert the loan
                         balance  into shares of the  Company's  common stock at
                         50%  of its  fair  market  value.  As a  result  of the
                         beneficial conversion feature an expense of $50,000 was
                         recorded upon  issuance.  On July 1, 2002, the note was
                         converted into 200,000 shares of common stock.

                         Effective August 5, 2002,  Rubicon cancelled all of the
                         stock options issued in the stock option plan, pursuant
                         to Rubicon's  Stock Plan,  which included stock options
                         issued to employees,  the board of  directors,  and the
                         medical  advisory  board which had  exercise  prices at
                         $1.00 and at $.60 per  share.  On August 5,  2002,  the
                         board   of   directors   unanimously   authorized   the
                         re-issuance  of the same  number  of stock  options  as
                         originally  granted in the Stock Plan, and issued those
                         shares at an exercise  price of $.34 per option,  which
                         was the closing price per share on August 5, 2002.



--------------------------------------------------------------------------------
                                                                               8
<PAGE>


Item 2.  Management's Discussion and Analysis or Plan of Operation.
         ----------------------------------------------------------

General.
--------

         The general  characteristics  of Rubicon Medical  Corporation  have not
changed since we filed our form 10-KSB Annual Report for the year ended December
31, 2001 and our post-effective  amendment to our Registration Statement on Form
SB-2, filed on April 22, 2002. Rubicon Medical Corporation  continues to conduct
research and development  activities to generate medical  technologies that will
be manufactured  and marketed  worldwide.  The primary focus of our research and
development  activities is the Rubicon Filter.  The Rubicon Filter is an embolic
protection  device  for use in  interventional  vascular  procedures  to  reduce
embolic  complications  during  stenting.  We intend to use the  Rubicon  Filter
platform to launch  additional  products  for use in various  other areas of the
vasculature system.

         Subsequent to the 2nd quarter ending June 30, 2002,  Rubicon  cancelled
all of the stock options issued in the stock option plan,  pursuant to Rubicon's
Stock Plan,  which  included  stock options  issued to  employees,  the board of
directors, and the medical advisory board which had exercise prices at $1.00 and
at $.60 per  share.  On  August 5,  2002,  the  board of  directors  unanimously
authorized  the  re-issuance  of the same number of stock  options as originally
granted in the Stock Plan,  and issued those shares at an exercise price of $.34
per option, which was the closing price per share on August 5, 2002.

Results of Operations
---------------------

         Operations had a net loss of $422,000 for the second quarter ended June
30, 2002 (Q2 '02),  compared  to a net profit of $92,000  for the quarter  ended
June 30, 2001 (Q2 '01).  The reasons for the change were as follows.  All of the
remaining  deferred  revenue that resulted from the initial  guardian  licensing
agreement  with Abbott  Laboratories  was earned and  recognized  in fiscal year
2001.  In  addition,  we also  completed  the  majority  of our  consulting  and
development  obligations related to the guardian project in 2001, which resulted
in development revenue of $117,000 for Q2 '02, compared to $464,000 for Q2 '01.

         Although  we  expect  to  receive  revenue  from the  guardian  license
agreement  with Abbott in the form of milestone  payments  related to regulatory
approvals,  there can be no assurances that any future revenue will be generated
from further development of the Guardian System.

         Revenue from  continuing  operations  for the six months ended June 30,
2002 (6M '02)  declined to $117,000  compared to  $1,066,000  for the six months
ended June 30, 2001 (6M '01). Once again, the primary reason for the decrease in
revenue  for 2002 is due to the  completion  of the  guardian  development,  and
$666,000 of deferred  revenue  that was earned and  recognized  in the first six
months of 2001. As a result, continuing operations had a net loss of $919,000 in
6M '02,  compared  to net income of  $198,000  for 6M '01.  Due to the nature of
research and development in the medical device industry,  the timing of revenues
generated  through the guardian system is unpredictable  and is dependant on the
terms of our existing licensing  agreement,  as well as regulatory  approvals in



--------------------------------------------------------------------------------
                                                                               9
<PAGE>

various  countries,  which are not under the control of Rubicon.  Therefore,  we
expect  any  future  revenues  to come  through  large  lump sum  payments,  and
eventually  through  royalties.  We  anticipate  our  operations  will  generate
revenues during 2002.  However, we cannot predict when such revenues will occur,
nor can we  guarantee  that any future  payments  will be  received  from Abbott
Laboratories pursuant to the licensing of the Guardian System.

         General and administrative (G&A) expenses for continuing operations for
Q2 '02 were  $242,000  compared to $150,000  for Q2 '01. G&A expenses for 6M '02
also  increased  to $566,000  compared to  $335,000 in 6M '01.  The  increase is
primarily due to the  following  factors.  First,  our  operations  justified an
allocation of $57,000 and $89,000 in operating expenses to cost of goods sold in
Q2 '01 and in 6M '01, respectively, compared to an allocation of $0 for the same
periods in 2002.  Second,  salaries for officers  increased due to the hiring of
Harold "Butch" Wolcott as Chief Operating  Officer,  nearly doubling the expense
for this account. Salaries for officers for Q2 '02 were $54,000 and $100,000 for
6M '02,  compared to $27,000 and $50,000 for the same periods in 2001.  Finally,
both our legal and investor relations expenses increased as a result of becoming
a public company. Legal expenses increased by approximately $15,000 and investor
relations  also  increased by $10,000 for 6M '02, and  essentially  remained the
same for Q2 2002, compared to the same periods in 2001.

         Interest expense  increased to $53,000 in Q2 '02 and $60,000 in 6M '02,
compared to $9,000 in Q2 '01 and $23,000 in 6M '01. A $50,000 non-cash  interest
charge resulted from the beneficial conversion feature associated with a $50,000
convertible  note issued during Q2 '02,  which was converted into 100,000 shares
of Rubicon Medical common stock, subsequent to June 30, 2002.

Liquidity and Capital Resources
-------------------------------

         Net  cash  used in  operating  activities,  including  adjustments  for
depreciation and other non- cash operating expenses, totaled $576,000 in 6M '02,
compared to $412,000 in 6M '01.  Cash used by  continuing  operations  in 6M '02
increased compared to 6M '01 primarily due to increased research and development
costs,  general and  administrative  costs and a reallocation  of resources from
discontinued to continuing operations. Continuing operations used $522,000 in 6M
'02,  compared to $277,000 in 6M '01. In Q1 '02,  Rubicon's  Board of  Directors
unanimously  determined  to  focus  solely  on the  technology  development  and
licensing business unit and voted to discontinue both the contract and equipment
manufacturing  segments of our  business.  During the first  quarter of 2002, we
fulfilled  all of the  obligations  that  existed  from our  remaining  contract
manufacturing customer work orders.  Therefore,  discontinued  operations had $0
revenues in Q2 '02 compared to $169,000 in Q2 '01. Operating  expenses,  related
to the discontinued  operations remained in Q2 '02, and discontinued  operations
used $54,000 in cash in 2002, compared to $135,000 in cash in 2001.

--------------------------------------------------------------------------------
                                                                              10
<PAGE>


         Cash flows used in investing  activities  were $50,000 in 2002 compared
to $53,000 in 2001.  Rubicon  invested  $43,000 in patent related costs in 2002,
compared to $0 investment  for the same period in 2001. In addition,  because of
Rubicon's  decision to eliminate certain business units,  investment in property
and equipment  decreased to $7,000 in 6M '02, compared to investments of $50,000
in 6M '01.

         Net cash provided by financing  increased to $318,000 in 2002, compared
to  $(328,000)  used in financing  activities  for the same period in 2001.  The
Company  received a total of $451,000  through both debt and equity financing in
2002, compared to $0 for the same period in 2001. Rubicon received $246,000 from
issuing 491,000 shares of its common stock. In addition,  the Company  increased
its debt  obligation by entering into long-term debt  agreements in exchange for
$205,000.  The Company  received  $155,000 from a related party and $50,000 from
the issuance of a convertible  note. An expense of $50,000 was  recognized  upon
issuance  of the  convertible  note  due  to a  beneficial  conversion  feature.
Subsequent to June 30, 2002, the holder of a $50,000  Convertible Note,  elected
to convert the unpaid  balance of $50,000 into shares of Rubicon  Medical common
stock at fifty percent (50%) of the average of the closing bid price on the days
preceding the date of the conversion. The Company intends to use these funds for
working capital. In addition, Rubicon's financing activities in 6M '02, included
$48,000 for principal  payments on long-term debt and $65,000 for the repurchase
of 50,000  shares of  Rubicon's  common  stock from the former owner of Accurate
Designs, as part of a settlement agreement between the two companies.

         Cash (and  equivalents)  were  $58,000  at June 30,  2002  compared  to
$628,000 at June 30,  2001.  Our  research  and  development  timetable  and the
development of the Rubicon Filter  required us to expend  substantial  resources
over the last twelve months.  The Company has had to support our operations with
existing  cash,  as well as cash raised  through the  private  placement  of our
securities.

         Rubicon has been successful in raising  additional  capital through the
private  placement of our  securities.  In October 2001,  our Board of Directors
authorized a private  placement of up to 3,000,000 shares of our common stock at
a price of $0.50 per share. As of June 30, 2002,  Rubicon has raised $986,500 in
exchange for the issuance of 1,871,000 shares of common stock. If our technology
development and licensing operations do not generate third quarter revenues,  we
intend to sell  additional  shares of common stock or raise  additional  capital
through  debt  financing.  Any future  capital  expenditures  will depend on the
manufacturing  requirements related to our existing technologies and our ability
to  market  these  technologies  effectively,  as well as our  ability  to raise
additional  capital.  There  can  be no  assurance  that  the  Company  will  be
successful in raising additional funding.


--------------------------------------------------------------------------------
                                                                              11
<PAGE>


Part II. Other Information


Item 1. Legal Proceedings
-------------------------

None; not applicable.


Item 2. Changes in Securities and Use of Proceeds.
-------------------------------------------------

See Part I, Item 2.


Item 3. Defaults Upon Senior Securities.
----------------------------------------

None; not applicable.


Item 4. Submission of Matters to a Vote of Security Holders.
------------------------------------------------------------

None; not applicable


Item 5. Other Information.
--------------------------

None; not applicable.


Item 6. Exhibits and Reports on Form 8-K.
----------------------------------------

None; not applicable.



--------------------------------------------------------------------------------
                                                                              12
<PAGE>


                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



Date:  August 14, 2002                               Rubicon Medical Corporation
                                                     /s/ Richard J. Linder
                                                     ---------------------------
                                                     Richard J. Linder
                                                     President / CEO

Date:  August 14, 2002
                                                     /s/ Dennis M. Nasella
                                                     ---------------------------
                                                     Dennis Nasella
                                                     CFO




--------------------------------------------------------------------------------
                                                                              13
<PAGE>

                            CERTIFICATION PURSUANT TO
                               18 U.S.C. ss. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of Rubicon  Medical  Corporation  (the
"Company") on Form 10-QSB for the period ending June 30, 2002, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Richard
J. Linder,  President/Chief  Executive Officer of the Company, certify, pursuant
to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge and belief:

         (1)  the Report fully complies with the  requirements  of Section 13(a)
              or 15(d) of the Securities Exchange Act of 1934; and

         (2)  the information  contained in the Report fairly  presents,  in all
              material   respects,   the  financial   condition  and  result  of
              operations of the Company.


Dated:  August 14, 2002                              By:  /s/ Richard J. Linder
        ---------------                              --------------------------
                                                     Richard J. Linder
                                                     President / CEO


--------------------------------------------------------------------------------
                                                                              14
<PAGE>


                            CERTIFICATION PURSUANT TO
                               18 U.S.C. ss. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of Rubicon  Medical  Corporation  (the
"Company")  on Form  10-Q/10-QSB  for the period  ending June 30, 2002, as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
I, Dennis Nasella, Chief Financial Officer of the Company,  certify, pursuant to
18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge and belief:

         (1)  the Report fully complies with the  requirements  of Section 13(a)
              or 15(d) of the Securities Exchange Act of 1934; and

         (2)  the information  contained in the Report fairly  presents,  in all
              material   respects,   the  financial   condition  and  result  of
              operations of the Company.



/s/Dennis Nasella
-----------------------
Dennis Nasella
Chief Financial Officer
August 14, 2002


--------------------------------------------------------------------------------
                                                                              15